Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them. The filing was signed on July 12, 2021.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| July 8, 2021 | Ordinary Shares (25p each) | £14.2450 | 1,800 shares | London Stock Exchange (XLON) |
Note: The total volume of 1,800 shares is the aggregate of six individual transactions listed in the filing.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely records routine share acquisitions resulting from dividend reinvestment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The nature of the transactions is strictly the acquisition of ordinary shares following the reinvestment of dividends paid to shareholders on July 8, 2021.
Key Facts for Investor Verification
- Transaction Type: All reported transactions were acquisitions of ordinary shares via dividend reinvestment, not open market purchases or sales.
- Participants: Transactions involved six individuals, including SVPs and a Company Secretary, as well as their closely associated persons.
- Share Price: All transactions executed at a uniform price of £14.2450 per share.
- Volume Distribution: The largest single transaction involved 1,202 shares acquired by a PCA of the Company Secretary; other transactions ranged from 1 to 544 shares.
- Financial Data: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F or earnings releases for performance metrics.